Three things to know about multi-state salmonella outbreak, egg recall
(NEW YORK) — A poultry farm in Wisconsin has recalled all of its eggs distributed in three states that the U.S. Centers for Disease Control and Prevention has linked to dozens of sicknesses as part of a Salmonella outbreak across nine states.
Details of multi-state salmonella outbreak, egg recall
Milo’s Poultry Farms LLC issued a recall on all carton sizes of all chicken egg types and expiration dates sold under two different labels, the U.S. Food and Drug Administration announced with the company on Sept. 6.
Milo’s Poultry Farms’ eggs were distributed in Wisconsin, Illinois, and Michigan through retail stores and food service distributors.
The Bonduel-based producer issued the recall on “Milo’s Poultry Farms” and “Tony’s Fresh Market” branded eggs, “because these eggs have the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems,” the company said in a statement.
“The recall was initiated after the FDA informed the company that environmental samples tested positive for the bacteria. FDA also conducted whole genome sequencing and found that the samples were related to an ongoing Salmonella outbreak investigation,” the company stated.
Milo’s Poultry Farms has ceased production and distribution as of the time of publication and “will undergo appropriate testing and sanitization of farms and processing equipment.”
The CDC has reported 65 total illnesses and 24 hospitalizations as of time of publication and the active investigation is ongoing.
Symptoms, side effects of salmonella
“Most people infected with Salmonella experience diarrhea, fever, and stomach cramps. Symptoms usually start 6 hours to 6 days after swallowing the bacteria. Most people recover without treatment after 4 to 7 days,” according to the CDC.
“Some people—especially children younger than 5 years, adults 65 years and older, and people with weakened immune systems—may experience more severe illnesses that require medical treatment or hospitalization,” the agency notes.
(NEW YORK) — The World Health Organization (WHO) declared mpox to be a public health emergency of international concern (PHEIC) on Wednesday
“Today, the Emergency Committee met and advised me that in its view, the situation constitutes a public health emergency of international concern. I have accepted that advice,” said WHO Director-General Dr. Tedros Adhanom Ghebreyesus during a media briefing on Wednesday.
In the U.S, there have been 1,634 cases of mpox reported so far this year, according to data from the U.S. Centers for Disease Control and Prevention (CDC).
That’s more than double the number of national cases seen at the same time last year but significantly lower than those seen during a U.S. mpox outbreak in 2022, CDC data shows.
PHEICs were most recently declared for the COVID-19 pandemic and the previous mpox outbreak of 2022.
Although mpox is endemic to parts of Central and Western Africa, cases have been rising dramatically in the Democratic Republic of the Congo (DRC).
This year, there have already been more than 14,000 mpox cases and 524 deaths reported in the DRC, according to the WHO.
There are two types of mpox: clade I and clade II, with clade roughly meaning they are descended from a common ancestor organism. While clade I has caused small, localized outbreaks in the DRC for years, researchers identified a clade I variant, known as clade Ib, that seems to spread mainly through sexual contact and appears to be behind the outbreak in the DRC.
Tedros said the detection of clade Ib in neighboring African countries that have never reported mpox cases before – including Burundi, Kenya, Rwanda and Uganda – led him to convene a meeting of the WHO’s emergency committee.
“The detection and rapid spread of a new clade of mpox in eastern DRC, its detection in neighboring countries that had not previously reported mpox, and the potential for further spread within Africa and beyond is very worrying,” Tedros said during the briefing.
On Monday, the Africa Centres for Disease Control and Prevention (Africa CDC) – the continent’s top health agency – declared mpox a public health emergency of continental security (PHECS) – the first such declaration since the Africa CDC’s inception in 2017, according to the agency.
On the same day, the WHO published a report that found there were a total of 934 new laboratory confirmed cases of mpox and four deaths from 26 countries in the month of June, “illustrating continuing transmission of mpox across the world.”
There have been no cases of clade I mpox reported outside Central and Eastern Africa at this time, including in the U.S., according to the CDC. The risk of the type of mpox circulating in the DRC is low to the American public, according to the CDC.
Currently, the JYNNEOS vaccine, a two-dose vaccine approved by the Food and Drug Administration to prevent smallpox and mpox, is the only vaccine being used in the U.S. to prevent mpox. Data from Africa has shown two doses of JYNNEOS are at least 85% effective in preventing mpox infection.
(WASHINGTON) When Congress passed the Inflation Reduction Act in 2022, there was a key provision that the Biden administration fought hard for. For years, private insurance companies negotiated with drug makers over prescription prices.
However, Medicare, representing 50 million seniors, did not have the same right to negotiate prices for its Part D coverage. This meant that Medicare basically had to accept the prices offered to them.
Health and Human Services Secretary Xavier Becerra joined “Start Here,” ABC News’ flagship daily news podcast, earlier this year to announce that negotiations were starting. They had selected 10 medications to prioritize and attempt to bargain down prices.
On Thursday, during the first public event held by President Biden and Vice President Harris since the Biden dropped out of the presidential race, they revealed that they had agreed on all issues. This is being described as a significant development for anyone on Medicare, and for anyone who pays taxes to fund the expenses of Medicare.
Secretary Becerra joined “Start Here” on Friday to discuss this further.
START HERE: Mr. Secretary, last time we spoke you had just identified the drugs…they included some diabetes drugs, some arthritis medications, treatments for blood clots and blood cancer. Where are we now?
BECERRA: We are done with the negotiation, Brad. We have completed 10 drugs. Every company joined in the negotiations. We had offers, counter offers, and we hit a sweet spot with all ten. And that sweet spot will save Americans on Medicare who need these drugs lots of money. And it will save taxpayers who help fund the Medicare program lots of money, in the billions.
START HERE: Yeah. How much of a discount are we talking about here?
BECERRA: So in some cases, the discount from the list price is up to 79%. I think the lowest discount is about 38%. And I do want to caveat that a bit. Very rarely does anybody pay list price for anything. And if you do, take it back and bargain a bit. Whether it’s that car at the dealership where you look at list price, you don’t pay that. When you go to the department store, you try to find everything you can on sale or, you know at some point it’s going to go on sale.
And so everybody makes the effort to try to get the best price for whatever the product is. In this case, it’s a very important product, it’s your prescription medication. But you should still be able to get a good price, and that’s what we did. We negotiated and got a much better price than what Medicare was getting.
START HERE: But just so we can we can be clear about that caveat. You’re saying it’s 68%, say it’s like 79% less than the list price. But you guys weren’t paying the list price earlier. Can you tell us how much you were paying on these drugs beforehand, and how much the new discount you’ve gotten is?
BECERRA: Yeah. And that’s where it gets a little dicey because there are lots of nooks and crannies in the health care system. Some of them include what are, what is considered proprietary information of the companies, the drug companies, that they don’t want disclosed. And so the net price that Medicare pays is lower than the list price, but still high.
START HERE: So there’s some contract somewhere being like “You guys, no one can disclose what you guys had originally been paying.”
BECERRA: Yeah. We can’t, we can’t take you behind the curtain unless the drug companies tell us it’s okay to do so.
START HERE: Were you able to actually push back against these drug companies, or was it kind of like “We’ll ask once and then we’ll have to take what we get. We’re not going to risk not giving Americans these, these drugs.”
BECERRA: Well, let’s just say that when they came in with their offer or counteroffer, the final price was neither our initial offer nor their official offer. But here’s what I will tell you. The Congressional Budget Office, which is Congress’ budget estimator, they’re the ones that keep tabs of what legislation will cost — will it save money or will it cost taxpayers money? And they are very stingy when it comes to saying “Oh, taxpayers will save money.” Right?
Well, the Congressional Budget Office said with regard to the Inflation Reduction Act and prescription drug negotiation, they said, we believe in the first year of negotiation — which we just finished — in that first year, and they’re projecting because they didn’t know which drugs it would be, etc.. They said, we believe the Department of Health Human Services will save $3.7 billion. Well, we’ve saved $6 billion.
And on top of that, we’re saving people out of pocket another billion and a half. But here’s the kicker. They said over 10 years, they assume that this new law, over 10 years of negotiating, will save $100 billion. So if we’re already almost double their first estimate for their first year, I guarantee you we’re going to do better than the 100 billion, over 10 years.
START HERE: Okay. When do the new prices go into effect, then I guess?
BECERRA: Jan. 1, 2026.
START HERE: Okay, so when that kicks in, how much of a discount will average Medicare patients actually see? Because, like, if you guys scored a 68% discount on Farxiga, like the diabetes kidney medication, does that mean that the person using that drug is going to pay, it doesn’t mean they’re going to pay 68% less. I mean, how much less would it be?
BECERRA: Yeah. So remember, and that’s also a difficult question because seniors don’t typically pay very much for their prescription medication. Medicare the program, that’s the beauty of Medicare, it covers the lion’s share of the cost of those drugs. Some Americans still have to pay some out-of-pocket costs for their drugs, especially the higher cost drugs. So we’re going to save folks quite a bit of money.
Let’s put it this way: I can talk to you in total aggregate terms. We can now look at the price that we negotiated and say “Okay, if we had this price back in 2023, what would our cost have been?” And the result is we would have saved $6 billion to the health care program, and Americans will be able to save about a billion and a half dollars collectively in their out-of-pocket costs.
START HERE: The trade group that represents companies like Pfizer, Lilly, Merck, they’ve said we might not see as much innovation because we’re not getting as much money. That’s, that’s constantly been sort of a critique of this. They also say that your math makes assumptions about how many people truly save money on this. They say a very small amount of people actually get this Part D plan in the way that would actually save the money here. What is your response to to to these pharmaceutical groups?
BECERRA: Well, remember, they’re more than 50 million Americans who have prescription coverage under Medicare, the Part D program. There are about 9 million people in the Medicare program who use one of these 10 drugs. It’s not a small universe of people. And these are very expensive drugs. When you can bring the price down of a drug that’s listed for, say, $10,000, $12,000 to $3,000. That’s a pretty good deal. It’s still $3,000, but it sure saved you a ton of money. If you were paid $12,000 or 13,000 before that.
And so this will save not just the Medicare program money, but it will save Medicare beneficiaries money. And it certainly will pay taxpayers who today, when they work, have some of their money from their paycheck taken out so they could cover their Medicare investment into the future so that when they get turned 65, they can qualify. They will get to benefit from a strengthened Medicare program that will have those new resources available, because we didn’t have to spend it at, for overcharging us for the prescription medication.
START HERE: Well, so now, I mean, the idea is that you’ll negotiate more drug prices, right? So you got these 10 out of the way. What are the next 10 or the next 20, or do you guys have a sense of what types of drugs you’re looking to target?
BECERRA: Yeah. And here I have to be careful, because everything we say about a drug can move the price on the market. Right? And I don’t want to be accused of trying to influence the price up or down. And so what I can tell you is the statute, the new law, the Inflation Reduction Act, gave a pretty clear prescription of how to select these, set of drugs that will be negotiated. That’s a, it’s a good thing in the way, in a sense that it doesn’t let politics enter into this. It was pretty clear which drugs count. In this case, the first 10, they had to be the most expensive drugs in the Medicare system.
START HERE: All right. So then we’ll see what happens next. All right. Secretary Xavier Becerra, thank you so much.
(NEW YORK) — As mosquito season continues, public health officials in the U.S. have been tracking several different illnesses caused by the pesky flying insect.
Health officials are reporting at least eighteen deaths from West Nile virus in the U.S. this year, with three recent deaths recorded in Wisconsin and Illinois. There have been six cases of eastern equine encephalitis (EEE), including one person who died after testing positive for the virus, as well as dengue cases recorded in several states. The viruses that cause all three illnesses are transmitted to humans via mosquito bite.
“What we’ve seen is a rapid uptake in certain viruses that haven’t been in the limelight in recent years. Both West Nile virus and ‘triple E,’ which is eastern equine encephalitis, have had an uptick, particularly post-COVID,” Dr. Larry Han, an assistant professor of public health and health sciences at Northeastern University in Boston, told ABC News.
“There’s also been a rise in dengue relative to what we’ve seen in recent years. And so, these ‘triple threats,’ you might say, have led to more attention and more worry among the general populace.”
Experts who spoke with ABC News said some of the uptick is due to the “randomness” regarding which seasons have a greater number of cases than others, coupled with the general rise in mosquito-borne viruses during the summer and early fall months.
Here are some ways to tell the difference between West Nile, EEE, and dengue. However, if you’re concerned you might have contracted any of these viruses, you should contact your doctor immediately.
How common are West Nile, EEE and dengue?
West Nile virus is the leading cause of mosquito-borne disease in the contiguous United States, according to the Centers for Disease Control and Prevention (CDC). It was first identified in the Western Hemisphere in August 1999 after people were diagnosed in New York City.
Dengue viruses are spread through bites from infected Aedes species mosquitoes, mostly found in tropical and subtropical regions of the world, according to the CDC. These mosquitoes are also responsible for spreading Zika and chikungunya viruses.
“It would be very rare to see dengue cases unless you lived in more tropical climates, so you might see this in Florida, some Southern states along the East Coast, but, for example, you would nearly never see this in Massachusetts or in the Midwest or West,” Han said.
Comparatively, EEE is quite rare, with only a few cases reported in the U.S. every year. However, similar to dengue, most cases occur in the Eastern or Gulf Coast states, according to the CDC.
What are the symptoms?
The majority of people with West Nile virus do not present with symptoms, but about one in five will experience fever along with headaches, body aches, joint pain, diarrhea, vomiting, or a rash. Symptoms typically disappear in a week or less for most people but weakness and fatigue may last for weeks or months. For some people, however, the disease can progress to something far more concerning.
“About one out of 150 of those people that develop signs and symptoms can actually develop a more severe disease, like West Nile encephalitis, where we have the swelling of the brain that could potentially be fatal,” Dr. Thomas Duszynski, director of epidemiology education at the Indiana University Richard M. Fairbanks School of Public Health, told ABC News.
Similarly, about one in four people who contract dengue develop symptoms lasting two to seven days, but symptoms are usually mild and may include fever, rash, nausea, vomiting, muscle pain, joint pain and bone pain.
Duszynski explained that most U.S. dengue cases are typically seen among people who contract it while traveling abroad, where dengue is endemic or where cases are more common, and who then bring the virus back to the U.S. Because dengue’s symptoms are not specific to the virus, they’re often confused with other illnesses, according to the CDC.
Most people who are infected with EEE show either mild symptoms or no symptoms at all, according to the CDC. However, severe cases typically present with fever, headache, chills and vomiting.
Like West Nile virus, EEE also can progress to a more severe condition, like encephalitis or meningitis, the latter of which is swelling of the membranes that surround the brain and spinal cord. Many survivors can experience ongoing neurologic problems, including convulsions, paralysis and intellectual disability. About 30% of encephalitis cases caused by EEE result in death.
“I think the mortality risk if one were to contract dengue or West Nile virus would be very low. For EEE, it’s the opposite; it’s very high,” Han said.
Treatments and vaccines
There are no disease-specific treatments for any of the viruses. The CDC recommends rest, fluids, and over-the-counter medications to relieve symptoms. Patients with severe illness often need to be hospitalized and receive additional supportive treatments, such as intravenous fluids.
There also are no vaccines available for West Nile or EEE. However, a dengue vaccine is available in the U.S. and is FDA approved for children between ages 9 and 16 who have a laboratory-confirmed previous dengue virus infection and who live in areas where dengue is endemic.
The vaccine also is available in Puerto Rico and is part of the territory’s routine childhood immunization schedule, the CDC said.
Dengue can be caused by dengue virus strains 1, 2, 3 or 4, with a person being infected multiple times over the course of their life, Duszynski told ABC News, so a vaccine may be able to help prevent infection from a different strain.
“If I got infected with one strain, if I get bit by this mosquito with the same strain, I’m probably going to be okay,’ he said. “But it’s those three other strains that are out there that … I could get infected with even though I had strain 1.”
How to best protect yourself from infection
There are no differences when it comes to protecting yourself from dengue, EEE or West Nile virus, the experts told ABC News. Prevention methods include using effective mosquito repellents, wearing long-sleeve shirts and long pants when outside, and staying in places with air conditioning, when possible. The CDC also recommends emptying containers of still or stagnant water, to eliminate places where mosquitos can breed.
“The single deadliest [animal] to the human species has been the mosquito,” Han said. “So, while we might think of sharks or we might think of lions or tigers, it’s really the mosquito that has led to the devastation of the human population multiple times throughout history.”
“I’m not saying that we should kill off all mosquitoes, because they play an important role in ecology, but there are various new techniques and strategies people are thinking about to combat mosquito-borne viruses and illnesses,” Han continued. “I’m hopeful that we can make mosquito borne viruses less of a threat to humanity.”